# EDGAR Filing Document

**Accession Number:** 0001641631
**File Stem:** 0001493152-25-021146
**Filing Date:** 2025-11
**Character Count:** 9214
**Document Hash:** 5c4f3a5fce1275031f15d364bfb37806
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021146.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001493152-25-021146

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251104

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lisi Steven A.
- **CENTRAL INDEX KEY:** 0001702628

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38892
- **FILM NUMBER:** 251460225

**MAIL ADDRESS:**
- **STREET 1:** 2 ILAN RAMON, SCIENCE PARK
- **CITY:** NESS ZIONA
- **STATE:** L3
- **ZIP:** 7403635
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Beyond Air, Inc.
- **CENTRAL INDEX KEY:** 0001641631
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473812456
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**BUSINESS ADDRESS:**
- **STREET 1:** 900 STEWART AVENUE
- **STREET 2:** SUITE 301
- **CITY:** GARDEN CITY
- **STATE:** NY
- **ZIP:** 11530
- **BUSINESS PHONE:** 516-665-8200

**MAIL ADDRESS:**
- **STREET 1:** 900 STEWART AVENUE
- **STREET 2:** SUITE 301
- **CITY:** GARDEN CITY
- **STATE:** NY
- **ZIP:** 11530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIT Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170117

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KokiCare, Inc.
- **DATE OF NAME CHANGE:** 20150507

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lisi Steven A.<br><sub>(Last) (First) (Middle)</sub><br>C/O BEYOND AIR, INC.<br>900 STEWART AVENUE, SUITE 301<br><sub>(Street)</sub><br>GARDEN CITY, NY 11530<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO and Chairman of the Board_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Beyond Air, Inc. [ XAIR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 47500 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 47500 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 47500 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 47500 | <sup>(1)</sup> | 47500 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 40000 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 40000 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 40000 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 40000 | <sup>(1)</sup> | 40000 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 14000 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 14000 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 14000 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 14000 | <sup>(1)</sup> | 14000 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 10000 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 10000 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 10000 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 10000 | <sup>(1)</sup> | 10000 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 3500 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 3500 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 3500 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 3500 | <sup>(1)</sup> | 3500 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 12500 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 12500 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 12500 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 12500 | <sup>(1)</sup> | 12500 | D |  |
| Stock Options (Right to buy) | $10.80 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 20000 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 20000 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 20000 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 20000 | <sup>(1)</sup> | 20000 | D |  |
| Stock Options (Right to buy) | $5.892 | 2025-11-04 |  | D<sup>(1)</sup> |  |  | 47500 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 47500 | <sup>(1)</sup> | 0 | D |  |
| Stock Options (Right to buy) | $1.95 | 2025-11-04 |  | A<sup>(1)</sup> |  | 47500 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 47500 | <sup>(1)</sup> | 47500 | D |  |

---

### Footnotes:

(1) On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

(2) This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

**Signature:** /s/ Steven A. Lisi  
**Date:** 2025-11-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**